Vor Biopharma Inc. (VOR): Price and Financial Metrics


Vor Biopharma Inc. (VOR): $5.27

0.30 (+6.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VOR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VOR Stock Price Chart Interactive Chart >

Price chart for VOR

VOR Price/Volume Stats

Current price $5.27 52-week high $9.72
Prev. close $4.97 52-week low $3.48
Day low $4.96 Volume 60,328
Day high $5.35 Avg. volume 101,986
50-day MA $5.78 Dividend yield N/A
200-day MA $5.03 Market Cap 203.77M

Vor Biopharma Inc. (VOR) Company Bio


Vor BioPharma Inc. operates as a clinical stage cell therapy company. The Company specializes in developing novel therapies for treating cancer. Vor BioPharma focuses on discovering technologies that can enable selective targeting of cancer cells without impacting normal cells. Vor BioPharma serves customers in the United States.


VOR Latest News Stream


Event/Time News Detail
Loading, please wait...

VOR Latest Social Stream


Loading social stream, please wait...

View Full VOR Social Stream

Latest VOR News From Around the Web

Below are the latest news stories about VOR BIOPHARMA INC that investors may wish to consider to help them evaluate VOR as an investment opportunity.

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33) in patients with acute myeloid leukemia (AML) has been accepted as a late-breaking poster presentation at the 2023 Tandem Meetings, the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, tak

Yahoo | January 19, 2023

Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference

CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities’ 3rd Annual Oncology Conference. B. Riley Securities’ 3rd Annual Oncology Conference – Fireside ChatDate: Wednesday, January 18, 2023Time: 12:00 PM ET A live webcast of the presentation will be available via the Investors section of the Company's website at www.vorbio.com. An archived repla

Yahoo | January 12, 2023

Vor Biopharma Inc. Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Vor Biopharma Inc. have earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat reports. One analyst has…

Business Mag | December 26, 2022

12-Month Price Target For Vor Biopharma Inc. (NASDAQ:VOR) Now Sits At $38.00

In last trading session, Vor Biopharma Inc. (NASDAQ:VOR) saw 0.38 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $7.07 trading at -$0.09 or -1.26% at ring of the bell on the day assigns it a market valuation of $271.21M. That closing price of VOR’s stock is … 12-Month Price Target For Vor Biopharma Inc. (NASDAQ:VOR) Now Sits At $38.00 Read More »

Marketing Sentinel | December 17, 2022

Bath & Body Works and Vor Biopharma Stock See Action From Activist Investors

Third Point disclosed a larger stake in body- and personal-care retailer Bath & Body Works. RA Capital more than doubled its stake in pharmaceutical firm Vor Biopharma.

Yahoo | December 16, 2022

Read More 'VOR' Stories Here

VOR Price Returns

1-mo -20.75%
3-mo 14.57%
6-mo 4.56%
1-year -36.12%
3-year N/A
5-year N/A
YTD -20.75%
2022 -42.77%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6857 seconds.